Results of retroviral and adenoviral approaches to cancer gene therapy.
Genetic modification for cancer treatment has involved the introduction of chemotherapy protection and sensitization genes into normal and tumor cells, respectively, for the purpose of improving the outcome of conventional approaches to the treatment of solid tumor neoplasms. This paper will review the use of multidrug resistance-1 retroviral vectors and cytosine deaminase adenoviral prodrug activation vectors for this purpose.
Yin
L H
LH
Yale Cancer Center, and Department of Internal Medicine of the Yale University School of Medicine, New Haven, Connecticut, USA.
Fu
S Q
SQ
Nanakorn
T
T
Garcia-Sanchez
F
F
Chung
I
I
Cote
R
R
Pizzorno
G
G
Hanania
E
E
Heimfeld
S
S
Crystal
R
R
Deisseroth
A
A
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000256:Adenoviridae; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D018014:Gene Transfer Techniques / Q000009:adverse effects; D019450:Genes, MDR; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy*; D012190:Retroviridae
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D016179:Granulocyte Colony-Stimulating Factor